{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:42:49Z","timestamp":1760298169321},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.3816\/clm.2009.n.055","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T01:06:30Z","timestamp":1251939990000},"page":"267-277","source":"Crossref","is-referenced-by-count":21,"title":["Mantle Cell Lymphoma: Biological Insights and Treatment Advances"],"prefix":"10.3816","volume":"9","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Sweetenham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.055_bib1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.hoc.2008.07.001","article-title":"Therapy of mantle cell lymphoma: current standards and future strategies","volume":"22","author":"Schmidt","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2009.n.055_bib2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","article-title":"The cellular origin of mantle cell lymphoma","volume":"39","author":"Bertoni","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.3816\/CLM.2009.n.055_bib3","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic hypermutation and V(H) gene usage in mantle cell lymphoma","volume":"68","author":"Thorselius","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.n.055_bib5","doi-asserted-by":"crossref","first-page":"692s","DOI":"10.1182\/blood.V108.11.2446.2446","article-title":"Improvement of overall survival in mantle cell lymphoma during the last decades","volume":"108","author":"Herrmann","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLM.2009.n.055_bib7","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","article-title":"Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene","volume":"13","author":"Bodrug","year":"1994","journal-title":"EMBO J"},{"key":"10.3816\/CLM.2009.n.055_bib8","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"key":"10.3816\/CLM.2009.n.055_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib10","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.055_bib11","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/16476","article-title":"The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus","volume":"397","author":"Jacobs","year":"1999","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.n.055_bib13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wildtype INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.055_bib14","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","article-title":"Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis","volume":"109","author":"Pinyol","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA damage response: putting checkpoints in perspective","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.n.055_bib16","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-007-0532-2","article-title":"MicroRNA: implications for cancer","volume":"452","author":"Sassen","year":"2008","journal-title":"Virchows Arch"},{"key":"10.3816\/CLM.2009.n.055_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","article-title":"microRNAs as oncogenes and tumor suppressors","volume":"302","author":"Zhang","year":"2007","journal-title":"Dev Biol"},{"key":"10.3816\/CLM.2009.n.055_bib20","unstructured":"Fu K. What is the role of microRNA? Presented at: the 2nd Global Workshop on Mantle Cell Lymphoma; Sonoma, CA; December 3-4, 2008."},{"key":"10.3816\/CLM.2009.n.055_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinaldi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.055_bib22","doi-asserted-by":"crossref","first-page":"8923","DOI":"10.1158\/0008-5472.CAN-07-2153","article-title":"Aberrant Huntingtin interacting protein 1 in lymphoid malignancies","volume":"67","author":"Bradley","year":"2007","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.055_bib23","unstructured":"Parekh S. Are there any epigenetic prognostic markers in MCL? Presented at: the 2nd Global Workshop on Mantle Cell Lymphoma; Sonoma, CA; December 3-4 2008."},{"key":"10.3816\/CLM.2009.n.055_bib24","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1084\/jem.20072102","article-title":"Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma","volume":"205","author":"Liu","year":"2008","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2009.n.055_bib25","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","article-title":"Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants","volume":"15","author":"Majlis","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","article-title":"Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma","volume":"69","author":"Raty","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.n.055_bib27","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular genetic characterization reveals new subsets of mantle cell lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.n.055_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group","volume":"64","author":"Weisenburger","year":"2000","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2009.n.055_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.055_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00428-005-0049-5","article-title":"Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients","volume":"448","author":"Schrader","year":"2006","journal-title":"Virchows Arch"},{"key":"10.3816\/CLM.2009.n.055_bib32","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib33","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib34","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib36","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","article-title":"Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors","volume":"25","author":"Kienle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib37","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","article-title":"Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue","volume":"26","author":"Hartmann","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.n.055_bib39","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib40","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib41","doi-asserted-by":"crossref","first-page":"422s","DOI":"10.1200\/jco.2006.24.18_suppl.7502","volume":"24","author":"Dreyling","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib42","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib45","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.n.055_bib47","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2000.18.4.773","article-title":"Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.n.055_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.n.055_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.833.833","article-title":"Rituximab (R) + hypercvad alternating with R-methotrexate\/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL)","volume":"112","author":"Romaguera","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib53","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multi center trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib54","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.055_bib55","first-page":"424s","article-title":"Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/High-dose methotrexate and cytarabine (M-C) (\u00b1rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3050.3050","article-title":"Rituximab plus hypercvad alternating with high dose methotrexate and cytarabine for patients with newly diagnosed mantle cell lymphoma. A multicenter trial from GISL","volume":"112","author":"Merli","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib57","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.n.055_bib59","first-page":"773a","article-title":"First report of the HOVON 45: a phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma","volume":"108","author":"Van't Veer","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib60","doi-asserted-by":"crossref","first-page":"866a","DOI":"10.1182\/blood.V108.11.3045.3045","article-title":"Frontline high dose sequential chemotherapy with rituximab (R-HDS) and autologous stem cell transplantation induces high rates of complete response and prolongs survival in mantle cell lymphoma (MCL)","volume":"108","author":"Cortelazzo","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib61","doi-asserted-by":"crossref","first-page":"774a","DOI":"10.1182\/blood.V108.11.2737.2737","article-title":"Immuno-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909","volume":"108","author":"Damon","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib62","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3597.3597","article-title":"High remission rates and prolonged progression free survival in newly diagnosed patients with mantle cell lymphoma treated with R-MACLO-IVAM-T","volume":"112","author":"Hosein","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximabpurged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib65","doi-asserted-by":"crossref","first-page":"868a","DOI":"10.1182\/blood.V108.11.3051.3051","article-title":"Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: extended follow-up of a matched pair analysis","volume":"108","author":"Hicks","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib66","doi-asserted-by":"crossref","first-page":"774a","DOI":"10.1182\/blood.V108.11.2737.2737","article-title":"Immuno-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909","volume":"108","author":"Damon","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib67","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib68","unstructured":"Gopal A. Allogeneic transplantation in MCL: registry data and trial results. Presented at: the 2nd Global Workshop on Mantle Cell Lymphoma; Sonoma, CA; December 3-4, 2008."},{"key":"10.3816\/CLM.2009.n.055_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2147.2147","article-title":"Sustained graft-versus-lymphoma effect among patients (pts) with mantle cell lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)","volume":"112","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib70","article-title":"Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. An analysis from the Lymphoma Working Party of the EBMT","volume":"112","author":"Robinson","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib71","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.055_bib74","first-page":"472s","article-title":"Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients","volume":"26","author":"Rummel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.055_bib76","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.389.389","article-title":"Phase II study of R-CHOP followed by 90YIbritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"110","author":"Smith","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.582.582","article-title":"Molecular remission after combined immunochemotherapy is of prognostic relevance in patients with MCL: results of the randomized intergroup trials of the European MCL Network","volume":"112","author":"Pott","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib78","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib79","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.055_bib80","first-page":"425s","article-title":"Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study","volume":"24","author":"Goy","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib81","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib83","doi-asserted-by":"crossref","first-page":"755a","DOI":"10.1182\/blood.V110.11.2563.2563","article-title":"Lenalidomide oral monotherapy produces a 53% response rate in patients with relapsed\/refractory mantle-cell non-Hodgkins lymphoma","volume":"110","author":"Tuscano","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.262.262","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantlecell lymphoma: results of an international study (NHL-003)","volume":"112","author":"Zinzani","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib85","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsiroli-mus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib86","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.leukres.2006.03.005","article-title":"Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells","volume":"30","author":"Smolewski","year":"2006","journal-title":"Leuk Res"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.055_bib87","first-page":"457s","article-title":"A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed\/refractory indolent and mantle cell lymphomas","volume":"26","author":"Gerecitano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib88","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.055_bib89","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.055_bib90","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib91","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.055_bib92","doi-asserted-by":"crossref","first-page":"44a","DOI":"10.1182\/blood.V110.11.121.121","article-title":"A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL)","volume":"110","author":"Reeder","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib93","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.055_bib94","unstructured":"Ansell S. mTOR inhibitors and lenalidomide for mantle cell lymphoma. Presented at: the 2nd Global Workshop on Mantle cell Lymphoma; Sonoma, CA; December 3-4, 2008."},{"key":"10.3816\/CLM.2009.n.055_bib95","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib96","doi-asserted-by":"crossref","first-page":"406a","DOI":"10.1182\/blood.V110.11.1351.1351","article-title":"Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib97","doi-asserted-by":"crossref","first-page":"120a","DOI":"10.1182\/blood.V110.11.385.385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"110","author":"Rummel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib98","doi-asserted-by":"crossref","first-page":"766a","DOI":"10.1182\/blood.V108.11.2710.2710","article-title":"Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkins lymphoma","volume":"108","author":"Van der Jagt","year":"2006","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.055_bib99","first-page":"449s","article-title":"Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: long-term follow-up of a phase II study","volume":"25","author":"Rummel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.055_bib100","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.6.6","article-title":"Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010)","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib101","doi-asserted-by":"crossref","first-page":"128a","DOI":"10.1182\/blood.V110.11.412.412","article-title":"Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma","volume":"110","author":"Weber","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.055_bib103","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.055_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1560.1560","article-title":"The efficacy and safety of lenalidomide oral monotherapy in patients with mantle cell lymphoma previously treated with bortezomib: pooled data from two phase II studies (NHL-002 and NHL-003)","volume":"112","author":"Reeder","year":"2008","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:09:20Z","timestamp":1590106160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1557919011700026"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.055","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}